Items related to Sensitising cervix against cancer: Addition of gemcitabine...

Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study - Softcover

 
9783659146695: Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study

Synopsis

The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer.

"synopsis" may belong to another edition of this title.

About the Author

Dr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Therapy delivery technique in Cervical Cancer and also delivers training & guidance to DNB PG trainees.

"About this title" may belong to another edition of this title.

Buy Used

Condition: As New
Like New Learn more about this copy

Shipping: US$ 33.30
From United Kingdom to U.S.A.

Destination, rates & speeds

Add to basket

Top Search Results from the AbeBooks Marketplace

Stock Image

Roy, Sanjoy; Mukherjee, Devleena; Lahiri, Debarshi
Published by LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New Softcover

Seller: Lucky's Textbooks, Dallas, TX, U.S.A.

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: New. Seller Inventory # ABLIING23Mar3113020265995

Contact seller

Buy New

US$ 50.94
Convert currency
Shipping: US$ 3.99
Within U.S.A.
Destination, rates & speeds

Quantity: Over 20 available

Add to basket

Stock Image

Sanjoy Roy
Published by LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New PAP
Print on Demand

Seller: PBShop.store UK, Fairford, GLOS, United Kingdom

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # IQ-9783659146695

Contact seller

Buy New

US$ 64.41
Convert currency
Shipping: US$ 4.38
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: 15 available

Add to basket

Stock Image

Sanjoy Roy
Published by LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New Softcover
Print on Demand

Seller: Ria Christie Collections, Uxbridge, United Kingdom

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9783659146695_lsuk

Contact seller

Buy New

US$ 59.45
Convert currency
Shipping: US$ 13.29
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: Over 20 available

Add to basket

Stock Image

Sanjoy Roy
Published by LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New PAP
Print on Demand

Seller: PBShop.store US, Wood Dale, IL, U.S.A.

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9783659146695

Contact seller

Buy New

US$ 73.16
Convert currency
Shipping: FREE
Within U.S.A.
Destination, rates & speeds

Quantity: Over 20 available

Add to basket

Stock Image

Roy, Sanjoy
ISBN 10: 3659146692 ISBN 13: 9783659146695
New PF

Seller: Chiron Media, Wallingford, United Kingdom

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

PF. Condition: New. Seller Inventory # 6666-IUK-9783659146695

Contact seller

Buy New

US$ 55.70
Convert currency
Shipping: US$ 20.63
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: 10 available

Add to basket

Seller Image

Sanjoy Roy
Published by LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New Taschenbuch
Print on Demand

Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. 76 pp. Englisch. Seller Inventory # 9783659146695

Contact seller

Buy New

US$ 56.38
Convert currency
Shipping: US$ 25.69
From Germany to U.S.A.
Destination, rates & speeds

Quantity: 2 available

Add to basket

Seller Image

Sanjoy Roy
Published by LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New Taschenbuch
Print on Demand

Seller: AHA-BUCH GmbH, Einbeck, Germany

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. Seller Inventory # 9783659146695

Contact seller

Buy New

US$ 58.01
Convert currency
Shipping: US$ 36.85
From Germany to U.S.A.
Destination, rates & speeds

Quantity: 2 available

Add to basket

Seller Image

Sanjoy Roy|Devleena Mukherjee|Debarshi Lahiri
Published by LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
New Kartoniert / Broschiert
Print on Demand

Seller: moluna, Greven, Germany

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Roy SanjoyDr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Thera. Seller Inventory # 5134864

Contact seller

Buy New

US$ 47.94
Convert currency
Shipping: US$ 54.72
From Germany to U.S.A.
Destination, rates & speeds

Quantity: Over 20 available

Add to basket

Stock Image

Roy, Sanjoy, Mukherjee, Devleena, Lahiri, Debarshi
Published by LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692 ISBN 13: 9783659146695
Used Paperback

Seller: Mispah books, Redhill, SURRE, United Kingdom

Seller rating 4 out of 5 stars 4-star rating, Learn more about seller ratings

Paperback. Condition: Like New. Like New. book. Seller Inventory # ERICA79636591466926

Contact seller

Buy Used

US$ 126.20
Convert currency
Shipping: US$ 33.30
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: 1 available

Add to basket